HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prior Dengue Virus Exposure Shapes T Cell Immunity to Zika Virus in Humans.

Abstract
While progress has been made in characterizing humoral immunity to Zika virus (ZIKV) in humans, little is known regarding the corresponding T cell responses to ZIKV. Here, we investigate the kinetics and viral epitopes targeted by T cells responding to ZIKV and address the critical question of whether preexisting dengue virus (DENV) T cell immunity modulates these responses. We find that memory T cell responses elicited by prior infection with DENV or vaccination with tetravalent dengue attenuated vaccines (TDLAV) recognize ZIKV-derived peptides. This cross-reactivity is explained by the sequence similarity of the two viruses, as the ZIKV peptides recognized by DENV-elicited memory T cells are identical or highly conserved in DENV and ZIKV. DENV exposure prior to ZIKV infection also influences the timing and magnitude of the T cell response. ZIKV-reactive T cells in the acute phase of infection are detected earlier and in greater magnitude in DENV-immune patients. Conversely, the frequency of ZIKV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in DENV-preexposed donors, compatible with more efficient control of ZIKV replication and/or clearance of ZIKV antigen. The quality of responses is also influenced by previous DENV exposure, and ZIKV-specific CD8 T cells from DENV-preexposed donors selectively upregulated granzyme B and PD1, unlike DENV-naive donors. Finally, we discovered that ZIKV structural proteins (E, prM, and C) are major targets of both the CD4 and CD8 T cell responses, whereas DENV T cell epitopes are found primarily in nonstructural proteins.IMPORTANCE The issue of potential ZIKV and DENV cross-reactivity and how preexisting DENV T cell immunity modulates Zika T cell responses is of great relevance, as the two viruses often cocirculate and Zika virus has been spreading in geographical regions where DENV is endemic or hyperendemic. Our data show that memory T cell responses elicited by prior infection with DENV recognize ZIKV-derived peptides and that DENV exposure prior to ZIKV infection influences the timing, magnitude, and quality of the T cell response. Additionally, we show that ZIKV-specific responses target different proteins than DENV-specific responses, pointing toward important implications for vaccine design against this global threat.
AuthorsAlba Grifoni, John Pham, John Sidney, Patrick H O'Rourke, Sinu Paul, Bjoern Peters, Sheridan R Martini, Aruna D de Silva, Michael J Ricciardi, Diogo M Magnani, Cassia G T Silveira, Alvino Maestri, Priscilla R Costa, Luzia Maria de-Oliveira-Pinto, Elzinandes Leal de Azeredo, Paulo Vieira Damasco, Elizabeth Phillips, Simon Mallal, Aravinda M de Silva, Matthew Collins, Anna Durbin, Sean A Diehl, Cristhiam Cerpas, Angel Balmaseda, Guillermina Kuan, Josefina Coloma, Eva Harris, James E Crowe Jr, Mars Stone, Phillip J Norris, Michael Busch, Hector Vivanco-Cid, Josephine Cox, Barney S Graham, Julie E Ledgerwood, Lance Turtle, Tom Solomon, Esper G Kallas, David I Watkins, Daniela Weiskopf, Alessandro Sette
JournalJournal of virology (J Virol) Vol. 91 Issue 24 (12 15 2017) ISSN: 1098-5514 [Electronic] United States
PMID28978707 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2017 American Society for Microbiology.
Chemical References
  • Dengue Vaccines
  • Epitopes, T-Lymphocyte
  • Vaccines, Attenuated
Topics
  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Cohort Studies
  • Cross Reactions
  • Dengue Vaccines (immunology)
  • Dengue Virus (immunology)
  • Epitopes, T-Lymphocyte (immunology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • T-Lymphocytes (immunology)
  • Vaccines, Attenuated (immunology)
  • Young Adult
  • Zika Virus (immunology)
  • Zika Virus Infection (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: